TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
about
[18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis.EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program.Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.PERCIST in Perspective.Assessment of very early response evaluation with 18F-FDG-PET/CT predicts survival in erlotinib treated NSCLC patients-A comparison of methods.
P2860
TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
TLG-S criteria are superior to ...... cinoma treated with erlotinib.
@en
type
label
TLG-S criteria are superior to ...... cinoma treated with erlotinib.
@en
prefLabel
TLG-S criteria are superior to ...... cinoma treated with erlotinib.
@en
P2093
P2860
P1476
TLG-S criteria are superior to ...... cinoma treated with erlotinib.
@en
P2093
Hsiao-Wen Chung
John Wen-Cheng Chang
Ming-Mo Hou
Nai-Ming Cheng
Tzu-Chen Yen
Tzu-Pei Su
Yu-Hua Dean Fang
Yuan-Chang Liu
P2860
P2888
P304
P356
10.1007/S00259-016-3433-2
P577
2016-06-03T00:00:00Z